Published in Law and Health Weekly, January 1st, 2005
Merck announced the special committee late December 7, 2004, saying it would act for the company's board of directors in handling shareholder litigation over the Vioxx withdrawal and would advise the board on any action to be taken after the review.
"This is exactly what you would expect the board to do in carrying out its duties to shareholders," said Merck spokeswoman Joan Wainwright.
She said the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.